WO2005118166A3 - Pharmaceutical composition containing irbesartan - Google Patents

Pharmaceutical composition containing irbesartan Download PDF

Info

Publication number
WO2005118166A3
WO2005118166A3 PCT/IB2005/002689 IB2005002689W WO2005118166A3 WO 2005118166 A3 WO2005118166 A3 WO 2005118166A3 IB 2005002689 W IB2005002689 W IB 2005002689W WO 2005118166 A3 WO2005118166 A3 WO 2005118166A3
Authority
WO
WIPO (PCT)
Prior art keywords
irbesartan
pharmaceutical composition
composition containing
formulation
provides
Prior art date
Application number
PCT/IB2005/002689
Other languages
French (fr)
Other versions
WO2005118166A2 (en
Inventor
Gershon Kolatkar
Erela Zisman
Original Assignee
Teva Pharma
Gershon Kolatkar
Erela Zisman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Gershon Kolatkar, Erela Zisman filed Critical Teva Pharma
Priority to JP2007514218A priority Critical patent/JP4880591B2/en
Priority to AU2005249794A priority patent/AU2005249794A1/en
Priority to PL05775601T priority patent/PL1750862T3/en
Priority to CA2568640A priority patent/CA2568640C/en
Priority to DE602005025755T priority patent/DE602005025755D1/en
Priority to EP05775601A priority patent/EP1750862B1/en
Priority to AT05775601T priority patent/ATE493973T1/en
Publication of WO2005118166A2 publication Critical patent/WO2005118166A2/en
Publication of WO2005118166A3 publication Critical patent/WO2005118166A3/en
Priority to IL179718A priority patent/IL179718A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85% of the Irbesartan is dissolved within about 30 minutes using USP apparatus 2, placing the tablet in 1000mL of 0.1N hydrochloric acid at 37°C with paddle speed of 50 rpm. The formulation can optionally contain at least one additional active ingredient.
PCT/IB2005/002689 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan WO2005118166A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2007514218A JP4880591B2 (en) 2004-06-04 2005-06-02 Pharmaceutical composition comprising irbesartan
AU2005249794A AU2005249794A1 (en) 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan
PL05775601T PL1750862T3 (en) 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan
CA2568640A CA2568640C (en) 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan
DE602005025755T DE602005025755D1 (en) 2004-06-04 2005-06-02 IRBESARTAN PHARMACEUTICAL COMPOSITION CONTAINING
EP05775601A EP1750862B1 (en) 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan
AT05775601T ATE493973T1 (en) 2004-06-04 2005-06-02 PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
IL179718A IL179718A0 (en) 2004-06-04 2006-11-30 Pharmaceutical composition containing irbesartan

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57742704P 2004-06-04 2004-06-04
US60/577,427 2004-06-04

Publications (2)

Publication Number Publication Date
WO2005118166A2 WO2005118166A2 (en) 2005-12-15
WO2005118166A3 true WO2005118166A3 (en) 2006-07-27

Family

ID=35463389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002689 WO2005118166A2 (en) 2004-06-04 2005-06-02 Pharmaceutical composition containing irbesartan

Country Status (11)

Country Link
US (2) US8226977B2 (en)
EP (1) EP1750862B1 (en)
JP (2) JP4880591B2 (en)
AT (1) ATE493973T1 (en)
AU (1) AU2005249794A1 (en)
CA (1) CA2568640C (en)
DE (1) DE602005025755D1 (en)
ES (1) ES2282062T1 (en)
IL (1) IL179718A0 (en)
PL (1) PL1750862T3 (en)
WO (1) WO2005118166A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1806130T1 (en) * 2006-01-09 2010-06-30 KRKA@@d@d@@@Novo@mesto Solid pharmaceutical composition comprising irbesartan
DE102006006588A1 (en) * 2006-02-13 2007-08-16 Ratiopharm Gmbh Fast-release irbesartan-containing pharmaceutical composition
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
JP5527921B2 (en) * 2006-12-22 2014-06-25 エスエス製薬株式会社 Oral solid composition concealing bitterness
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
RU2010104960A (en) * 2007-08-01 2011-09-10 Тева Фармасьютикал Индастриес Лтд. (Il) PHARMACEUTICAL COMPOSITION OF CANDESARTAN
PT2065035E (en) * 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Pharmaceutical formulations containing irbesartan
JP5296456B2 (en) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
WO2011010316A1 (en) * 2009-07-20 2011-01-27 Hetero Research Foundation Pharmaceutical compositions of irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
JP5946135B2 (en) * 2012-03-29 2016-07-05 塩野義製薬株式会社 Solid formulation containing trichloromethiazide and crystalline cellulose
JP6018420B2 (en) * 2012-06-05 2016-11-02 ニプロ株式会社 Pharmaceutical composition comprising an angiotensin II receptor antagonist and thiazide diuretic
KR20140030505A (en) * 2012-08-31 2014-03-12 한미약품 주식회사 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
JP5714652B2 (en) * 2013-06-13 2015-05-07 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP5978335B2 (en) * 2015-03-11 2016-08-24 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
JP6445923B2 (en) * 2015-04-22 2018-12-26 ダイト株式会社 Preparation of irbesartan-containing tablets
JP6737060B2 (en) * 2015-09-11 2020-08-05 ニプロ株式会社 Method for producing pharmaceutical composition containing irbesartan
JP6151413B2 (en) * 2016-07-25 2017-06-21 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
JP2017141299A (en) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet
JP2018168185A (en) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition and orally disintegrable tablet with excellent elution
JP2019203031A (en) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6051594A (en) * 1995-04-28 2000-04-18 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
US6457510B1 (en) * 1997-09-01 2002-10-01 Vulcan Engineering Company, Inc. Method for compacting moulding sand

Family Cites Families (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327080A (en) 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US5002776A (en) 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US5049394A (en) 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5212165A (en) 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2681067B1 (en) 1991-09-10 1993-12-17 Elf Sanofi N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2665702B1 (en) 1990-08-08 1994-02-25 Sanofi N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2659967B1 (en) 1990-03-20 1992-07-24 Sanofi Sa N-SUBSTITUTED IMIDAZOLINONE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5137902A (en) 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
US5089626A (en) 1990-08-23 1992-02-18 Merck & Co., Inc. Process for preparing an angiotensin II antagonist
US5032578A (en) 1990-09-17 1991-07-16 E. R. Squibb & Sons, Inc. Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
US5098889A (en) 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
ATE177634T1 (en) 1990-12-14 1999-04-15 Smithkline Beecham Corp ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US6034114A (en) 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
US20010016594A1 (en) 1990-12-14 2001-08-23 Smithkline Beecham P.L.C. Medicament
US6025380A (en) 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
FR2673427B1 (en) 1991-03-01 1993-06-18 Sanofi Elf N-SUBSTITUTED DIAZOTATED HETEROCYCLIC DERIVATIVES BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2677984B1 (en) 1991-06-21 1994-02-25 Elf Sanofi N-SUBSTITUTED IMIDAZOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
DK0521388T3 (en) 1991-07-01 1995-09-11 Gergely Gerhard Process for the preparation of a pharmaceutical composition having at least two different active substances and the use of such a preparation
AU2496492A (en) 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
AU2494792A (en) 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
ATE216577T1 (en) 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd QUICK DISSOLVABLE TABLET AND PRODUCTION THEREOF
FR2688781B1 (en) 1992-03-23 1994-07-01 Sanofi Elf IMIDAZOLINES N-SUBSTITUTED BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB9208116D0 (en) 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
US6673824B1 (en) 1992-05-06 2004-01-06 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
EP0577023A3 (en) 1992-07-01 1996-12-18 Hoechst Ag Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
US5457112A (en) 1992-12-14 1995-10-10 Synthelabo 3-(6-quinolylmethyl)-4H-imidazol-4-one derivatives, their preparation and their application in therapy
DE69433723T3 (en) 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0635263A3 (en) 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue.
FR2708608B1 (en) 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
FR2708606B1 (en) 1993-07-30 1995-10-27 Sanofi Sa N-phenylalkylindol-2-one derivatives, their preparation, pharmaceutical compositions containing them.
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5824696A (en) 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US6174917B1 (en) 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
DE69434626D1 (en) 1993-11-17 2006-04-20 Athena Neurosciences Inc TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS
US5523095A (en) 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5536505A (en) 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
JPH09508641A (en) 1994-02-08 1997-09-02 チバーガイギー アクチエンゲゼルシャフト Treatment of normal tension glaucoma with angiotensin II antagonist
JP3414539B2 (en) 1994-05-11 2003-06-09 有限会社ドット Composition for nasal absorption
US6645463B1 (en) 1994-05-16 2003-11-11 The Board Of Regents Of The University Of Michigan Blood-pool selective carrier for lipophilic imaging agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5541209A (en) 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
FR2725987B1 (en) 1994-10-19 1997-01-10 Sanofi Sa PROCESS FOR THE PREPARATION OF A TETRAZOLE DERIVATIVE IN TWO CRYSTALLINE FORMS AND NOVEL CRYSTALLINE FORM THEREOF
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5780473A (en) 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
CA2168066A1 (en) 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
FR2732223B1 (en) 1995-03-30 1997-06-13 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US20020094346A1 (en) 1995-05-17 2002-07-18 M. D. Henry C. Lin Method and compositions for improving digestion and absorption in the small intestine
SE9501881D0 (en) 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII receptor antagonists
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
RO118046B1 (en) 1995-06-07 2003-01-30 Gd Searle & Co Chicago Pharmaceutical association
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2735365B1 (en) 1995-06-14 1997-09-05 Sanofi Sa USE OF AN ANGIOTENSIN II ANTAGONIST AND A BENZOFURANE DERIVATIVE FOR THE PREPARATION OF A MEDICAMENT USEFUL IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS
SE9502219D0 (en) 1995-06-19 1995-06-19 Astra Ab Novel medical use
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
FR2740136B1 (en) 1995-10-24 1998-01-09 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2740686B1 (en) 1995-11-03 1998-01-16 Sanofi Sa STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION
JP4369994B2 (en) 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト AT for lowering apoptosis 1 Receptor antagonist
FR2746013B1 (en) 1996-03-18 1998-05-29 Sanofi Sa USE OF ANTIARRHYTHMIC COMPOUNDS IN THE PREVENTION OF POST INFARCT MORTALITY
US5939446A (en) 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
DE69734405T2 (en) 1996-07-15 2006-08-03 Sankyo Co., Ltd. Use of CS-866 (Olmersartan) for the manufacture of a medicament for the treatment of arteriosclerosis
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
ES2257771T3 (en) 1996-10-28 2006-08-01 Amersham Health As CONTRAST AGENTS.
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6019988A (en) 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
FR2757157B1 (en) 1996-12-13 1999-12-31 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
EP0855392A3 (en) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5846985A (en) 1997-03-05 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
TW580397B (en) 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
DE19724696A1 (en) 1997-06-12 1998-12-24 Hexal Ag Pharmaceutical preparation with three types of pellets
ATE261721T1 (en) 1997-06-13 2004-04-15 Nanopharm Ag SYSTEM FOR THE TARGETED DELIVERY OF ACTIVE INGREDIENTS, METHOD FOR ITS PRODUCTION AND USE
IT1292437B1 (en) 1997-06-30 1999-02-08 Zambon Spa ORTHO-METALLATION PROCESS USEFUL FOR THE SYNTHESIS OF 1 - TETRAZOL- 5-IL) 2-SUBSTITUTED BENZENES
HU218679B (en) 1997-07-25 2000-10-28 Sanofi-Synthelabo Process for preparation of imidazolones and intermediates thereof
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
GT199800126A (en) 1997-08-29 2000-01-29 COMBINATION THERAPY.
AU747252B2 (en) 1997-09-09 2002-05-09 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
PL197164B1 (en) 1997-10-17 2008-03-31 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
JPH11137208A (en) 1997-11-14 1999-05-25 Nikken Chem Co Ltd Solid material rapidly soluble in oral cavity and its production
DE19750529A1 (en) 1997-11-14 1999-05-20 Basf Ag New heterocyclic alpha-hydroxycarboxylic acid derivatives useful for treating hypertension, chronic coronary insufficiency, asthma, prostate cancer etc.
HUP0100469A2 (en) * 1997-12-19 2001-08-28 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
US6162922A (en) 1998-01-30 2000-12-19 Bristol-Myers Squibb Co. Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6300356B1 (en) 1998-02-25 2001-10-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
ZA991706B (en) 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
FR2775598A1 (en) 1998-03-06 1999-09-10 Sanofi Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS
US6284363B1 (en) 1998-03-23 2001-09-04 Fuji Polymer Industries Co., Ltd. Electromagnetic wave absorbing thermoconductive silicone gel molded sheet and method for producing the same
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
FR2778103A1 (en) 1998-04-29 1999-11-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
EP1428531A1 (en) 1998-05-11 2004-06-16 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
ES2246575T3 (en) 1998-06-17 2006-02-16 Bristol-Myers Squibb Company PREVENTION OF THE BRAIN INFARCUS THROUGH THE ADMINISTRATION OF A COMBINATION OF AN ADP RECEPTOR BLOCKING ANTIPLAQUETARY PHARMACO AND AN ANTIHIPERTENSIVE PHARMACO.
IT1301759B1 (en) 1998-06-19 2000-07-07 Nicox Sa NITRATED SALTS OF ANTI-HYPERTENSIVE DRUGS
FR2780403B3 (en) * 1998-06-24 2000-07-21 Sanofi Sa NOVEL FORM OF IRBESARTAN, METHODS FOR OBTAINING SAID FORM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
FR2780890B3 (en) 1998-07-10 2000-09-01 Sanofi Sa USE OF A PHARMACEUTICAL COMPOSITION CONTAINING, IN COMBINATION, AN ANTAGONIST OF ANGIOTENSIN II AT1 RECEPTORS AND INDOMETHACIN FOR THE TREATMENT OF CHRONIC GLOMERULONEPHRITES
ES2347968T3 (en) 1998-07-28 2010-11-26 Takeda Pharmaceutical Company Limited SOLID PREPARATION THAT DISAPPEARS RAPIDLY.
CA2340206A1 (en) 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
FR2783422A1 (en) 1998-09-21 2000-03-24 Sanofi Sa Composition for reducing treating hypertension or platelet aggregation disorders, contains angiotensin II receptor antagonist and platelet anti-aggregation agent
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6364865B1 (en) 1998-11-13 2002-04-02 Elan Pharma International Limited Drug delivery systems and methods
TNSN99224A1 (en) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc METHODS OF REDUCING GLUCOSE AND TRIGLYCERIDE LEVELS IN SERUM AND FOR ANTIGENESIS SUPPRESSION USING INDOLEALKANOIC ACIDS
FR2787330A1 (en) 1998-12-18 2000-06-23 Sanofi Sa Compositions containing an immunosuppressant and an AT1 angiotensin II receptor antagonist, for prevention and treatment of vascular complications due to graft rejection
KR100349597B1 (en) 1999-01-12 2002-08-22 삼성전자 주식회사 Optical wave-guide device and manufacturing method thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
DK1169322T3 (en) 1999-03-08 2006-03-06 Medicure Inc Pyridoxal analogues for the treatment of disorders caused by vitamin B6 deficiency
JP3695978B2 (en) 1999-03-16 2005-09-14 三洋電機株式会社 Alkaline storage battery with spiral electrode body
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
AU5886900A (en) 1999-06-25 2001-01-31 Institutes For Pharmaceutical Discovery, Llc, The Substituted phenoxyacetic acids
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
SE9902597D0 (en) 1999-07-06 1999-07-06 Astra Ab New use
JP2003507418A (en) 1999-08-24 2003-02-25 メディキュア インターナショナル インコーポレイテッド Treatment of cardiovascular disease and related diseases
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
US20030225124A1 (en) 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US6555551B1 (en) 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
CA2383974A1 (en) 1999-09-08 2001-03-15 Nitromed Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001028548A1 (en) 1999-10-19 2001-04-26 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
EP1093814A1 (en) 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2001035961A1 (en) 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20030113330A1 (en) 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1106210A3 (en) 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
FR2803525B1 (en) 2000-01-06 2002-05-03 Sod Conseils Rech Applic SIGNAL TRANSDUCTION INHIBITOR OF HETEROTRIMERIC PROTEINS ASSOCIATED WITH AN ANTI-HYPERTENSION AGENT IN THE TREATMENT OF ARTERIAL HYPERTENSION
CA2396596A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
KR20030016229A (en) 2000-02-18 2003-02-26 다케다 야쿠힌 고교 가부시키가이샤 TNF-αINHIBITORS
US20030068374A1 (en) 2000-02-21 2003-04-10 Shigeru Kamei Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
US20030152636A1 (en) 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
JP2003525303A (en) 2000-02-29 2003-08-26 メディキュア インターナショナル インコーポレイテッド Cardioprotective phosphonates and malonates
AU2001238718A1 (en) 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
CN1768735A (en) 2000-03-17 2006-05-10 味之素株式会社 Medicaments for diabetic complication and neuropathy, and uses thereof
DE10014588A1 (en) 2000-03-27 2001-10-04 Basf Ag Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone
US6436684B1 (en) 2000-03-27 2002-08-20 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2001072335A2 (en) 2000-03-28 2001-10-04 Queen's University At Kingston Methods for effecting neuroprotection using a potassium channel modulator
EP1277730A4 (en) 2000-03-28 2005-03-16 Neovascularization inhibitors
DE10015479A1 (en) 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
EP1267855A2 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Company Vasopeptidase inhibitors to treat isolated systolic hypertension
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
JP2003530383A (en) 2000-04-11 2003-10-14 アセロジエニクス・インコーポレイテツド Compounds and methods for increasing plasma HDL cholesterol levels and improving HDL functionality
US20030083342A1 (en) 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
CN1440283A (en) 2000-04-12 2003-09-03 诺瓦提斯公司 Combination of organic compounds
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
AR030557A1 (en) 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
AU2001259671B2 (en) 2000-05-10 2004-06-24 Rtp Pharma Inc. Media milling
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AU2001264729A1 (en) 2000-05-22 2001-12-03 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
EP1284260A4 (en) 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd Tyrosine phosphatase inhibitors
AU6972901A (en) 2000-05-31 2001-12-11 Mayo Foundation Cobalamin compounds useful as cardiovascular agents and as imaging agents
US20030212124A1 (en) 2001-05-30 2003-11-13 Kevorkian Robert C. Use of ace inhibitors for treatment of patients suffering from behavioral disorders
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7678387B2 (en) 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DE10029201A1 (en) 2000-06-19 2001-12-20 Basf Ag Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
EP1889633B1 (en) 2000-06-27 2011-10-26 AnGes MG, Inc. Medicinal compositions for angiogenic therapy
US20030114420A1 (en) 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US7799794B2 (en) 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
AU2001279284A1 (en) 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
WO2002004421A2 (en) 2000-07-07 2002-01-17 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
CN1441794A (en) 2000-07-13 2003-09-10 武田药品工业株式会社 Lipid-rich plague inhibitors
US20020068729A1 (en) 2000-07-13 2002-06-06 Alteon, Inc. Method for treating fibrotic diseases or other indications IC
US20030176426A1 (en) 2000-07-13 2003-09-18 Alteon, Inc. Method for treating fibrotic diseases or other indications with imidazolium agents
EP1368009A2 (en) 2000-07-27 2003-12-10 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
GB0020691D0 (en) 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
CA2420055C (en) 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US6521747B2 (en) 2000-08-28 2003-02-18 Genaissance Pharmaceuticals, Inc. Haplotypes of the AGTR1 gene
AU2001284413A1 (en) 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
US6595926B1 (en) 2000-09-07 2003-07-22 John H. Laragh Method for evaluating and treating hypertension
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020048599A1 (en) 2000-10-20 2002-04-25 Thomas H. Mueller Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
CN1714084A (en) 2000-10-26 2005-12-28 辉瑞产品公司 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
CA2650698C (en) 2000-11-17 2013-05-28 Takeda Pharmaceutical Company Limited Copolyvidone-containing preparation
US6670380B2 (en) 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
JP4107831B2 (en) 2000-11-21 2008-06-25 第一三共株式会社 Pharmaceutical composition
WO2002045431A2 (en) 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US20040087484A1 (en) 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
WO2002053573A1 (en) 2000-12-28 2002-07-11 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc Method for treating fibrotic diseases or other indications
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
WO2002067851A2 (en) 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
ITMI20010129A1 (en) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
CA2434436A1 (en) 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
RS51449B (en) 2001-01-26 2011-04-30 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1671650A1 (en) 2001-01-26 2006-06-21 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
SI1363668T1 (en) 2001-01-26 2007-12-31 Schering Corp Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PT1353694E (en) 2001-01-26 2008-03-12 Schering Corp Combinations of ezetimibe with aspirine for treating vascular conditions
CA2436774A1 (en) 2001-01-30 2002-08-08 R. Michael Lawrence Sulfonamide lactam inhibitors of factor xa
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
FI114483B (en) 2001-02-20 2004-10-29 Jurilab Ltd Oy Procedure for detecting a risk of elevated blood pressure and its uses
WO2002068439A1 (en) 2001-02-26 2002-09-06 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
ES2350084T3 (en) 2001-02-27 2011-01-18 Kissei Pharmaceutical Co., Ltd. DERIVATIVES OF GLUCOPIRANOSILOXIPIRAZOL AND MEDICAL USE OF THE SAME.
EP1236720B1 (en) 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
US20030119010A1 (en) 2001-03-01 2003-06-26 University Of Queensland Polynucleotides and polypeptides linked to a disease or condition
CA2437594A1 (en) 2001-03-02 2002-09-12 Graham S. Poindexter Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
JP2005506286A (en) 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー Combined administration of melanocortin receptor agonist and phosphodiesterase inhibitor for the treatment of cyclic-AMP related diseases
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6642244B2 (en) 2001-03-16 2003-11-04 Bristol-Myers Squibb Co. Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase
CN1215067C (en) 2001-03-30 2005-08-17 辉瑞产品公司 Pyridazinone aldose reductase inhibitors
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US6774112B2 (en) 2001-04-11 2004-08-10 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
US20030004199A1 (en) 2001-04-12 2003-01-02 Isabelle Ounis Method for preventing or treating pulmonary inflammation by administering an endothelin antagonist
US7235523B2 (en) 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
WO2002087503A2 (en) 2001-04-26 2002-11-07 Vanderbilt University Compositions and methods for treating colorectal polyps and cancer
DE60233140D1 (en) 2001-05-02 2009-09-10 Nitromed Inc NITROSED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHOD OF USE
US20020168393A1 (en) 2001-05-08 2002-11-14 Ryota Sugimoto Implantable medical material and implantable medical device
CA2445913A1 (en) 2001-05-14 2003-10-29 Merck & Co., Inc. Method of treatment
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20030078190A1 (en) 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
US20030060451A1 (en) 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
EP1406611A2 (en) 2001-05-30 2004-04-14 Alteon, Inc. Method for treating fibrotic diseases or other indications
US20030092736A1 (en) 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
WO2002096362A2 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications vi
US20040156903A1 (en) 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
MXPA03011910A (en) 2001-06-18 2004-06-03 Noven Pharma Enhanced drug delivery in transdermal systems.
WO2003006023A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Company Pyrazinone inhibitors of fatty acid binding protein and method
US20030158090A1 (en) 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US6670386B2 (en) 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1425015A4 (en) 2001-08-20 2004-12-15 Bristol Myers Squibb Co Tetrahydroquinoline derivatives as antithrombotic agents
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP4450365B2 (en) 2001-08-28 2010-04-14 シェーリング コーポレイション Polycyclic guanine phosphodiesterase V inhibitor
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
WO2003023066A1 (en) 2001-09-11 2003-03-20 The Regents Of The University Of Colorado, A Body Corporate Expression profiling in the intact human heart
US6638542B2 (en) 2001-09-20 2003-10-28 Nutricia N.V. Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20030119808A1 (en) 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US20030114469A1 (en) 2001-09-27 2003-06-19 Cohen David Saul Combinations
EP1298223A3 (en) 2001-09-28 2003-07-23 Pfizer Products Inc. Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene
CA2461705A1 (en) 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
WO2003033671A2 (en) 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
FR2831446B1 (en) 2001-10-26 2004-03-05 Sanofi Synthelabo USE OF IRBESARTAN FOR THE PREPARATION OF MEDICINES USEFUL FOR THE PREVENTION OR TREATMENT OF PULMONARY HYPERTENSION
AU2916902A (en) 2001-10-29 2003-05-01 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Glycogen synthase kinase function in endothelial cells
US20030083614A1 (en) 2001-10-30 2003-05-01 Boehringer Ingelheim Pharma Kg Controlled release endoprosthetic device
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
WO2003040114A1 (en) 2001-11-06 2003-05-15 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1442042A1 (en) 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ATE374183T1 (en) 2001-11-13 2007-10-15 Schering Corp NK1 ANTAGONISTS
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003050110A1 (en) 2001-12-10 2003-06-19 Dr. Reddy's Laboratories Ltd. Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
PE20030762A1 (en) 2001-12-18 2003-09-05 Schering Corp HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
ATE404544T1 (en) 2001-12-19 2008-08-15 Bristol Myers Squibb Co CONDENSED HETEROCYCLIC COMPOUNDS AND ANALOGUES THEREOF; MODULATORS OF THE FUNCTION OF NUCLEAR HORMONE RECEPTORS
US20030144269A1 (en) 2001-12-20 2003-07-31 Block Alan J. Reducing pulse pressures and vascular stiffness in hypertensive patients by administering a vasopeptidase inhibitor
ATE374602T1 (en) 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc ORAL CAPSULE FORMULATION WITH IMPROVED PHYSICAL STABILITY
EP1461070B1 (en) 2001-12-29 2007-01-24 Novo Nordisk A/S Combined use of a glp-1 compound and an aldose reductase inhibitor
US20030220297A1 (en) 2002-02-01 2003-11-27 Berstein David L. Phosphorus-containing compounds and uses thereof
EA010860B1 (en) 2002-02-06 2008-12-30 Викор Текнолоджиз, Инк. Anti-infarction molecules
US20030221207A1 (en) 2002-02-13 2003-11-27 Pharmacia Corporation, Global Patent Department Cardiac-specific 11beta hydroxysteroid dehydrogenase type 2 transgenic mice
WO2003070278A1 (en) 2002-02-19 2003-08-28 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
US6951869B2 (en) 2002-02-26 2005-10-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring
PL372887A1 (en) 2002-02-27 2005-08-08 Pfizer Products Inc. Acc inhibitors
US20040116510A1 (en) 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
CN101143221A (en) 2002-03-15 2008-03-19 布赖汉姆妇女医院 Central airway administration for systemic delivery of therapeutics
ES2268327T3 (en) 2002-03-18 2007-03-16 Pfizer Products Inc. USE OF A SELECTIVE OF AN EP4 RECEIVER FOR THE TREATMENT OF DISEASES.
US20030199424A1 (en) 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis
EP1490044A4 (en) 2002-03-29 2008-04-16 Neurogen Corp Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20030203915A1 (en) 2002-04-05 2003-10-30 Xinqin Fang Nitric oxide donors, compositions and methods of use related applications
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
AU2003225102A1 (en) 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
ATE304015T1 (en) 2002-04-26 2005-09-15 Pfizer Prod Inc TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRION METALLOPROTEINASE INHIBITORS
US20030203027A1 (en) 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
CA2480092A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EP1982719A1 (en) 2002-04-26 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
CA2483500A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
NI200300045A (en) 2002-04-26 2005-07-08 Pfizer Prod Inc INHIBITORS OF TRIARILOXIARILOXIPIRIMIDIN-2,4,6-METALOPROTEINASE TRION.
US20030203019A1 (en) 2002-04-30 2003-10-30 Cornelius John Mark Coated conditioners for use in foods and pharmaceuticals
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7276514B2 (en) 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
AUPS236902A0 (en) 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7375138B2 (en) 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2003099206A2 (en) 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
US20030229007A1 (en) 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
JP2005529933A (en) 2002-05-31 2005-10-06 シェーリング　コーポレイション Xanthine phosphodiesterase V inhibitor polymorph
US20030233118A1 (en) 2002-06-13 2003-12-18 Hui John C. K. Method for treating congestive heart failure using external counterpulsation
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
WO2003103632A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
WO2003106628A2 (en) 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
US6846838B2 (en) 2002-06-19 2005-01-25 Bristol-Myers Squibb Company Ureido-substituted aniline compounds useful as serine protease inhibitors
EP1382334A1 (en) 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
ATE458534T1 (en) 2002-10-04 2010-03-15 Microchips Inc MEDICAL DEVICE FOR CONTROLLED DRUG ADMINISTRATION AND CARDIAC MONITORING AND/OR HEART STIMULATION
US20040106954A1 (en) 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7268157B2 (en) 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051594A (en) * 1995-04-28 2000-04-18 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
US6457510B1 (en) * 1997-09-01 2002-10-01 Vulcan Engineering Company, Inc. Method for compacting moulding sand

Also Published As

Publication number Publication date
ES2282062T1 (en) 2007-10-16
US20050271720A1 (en) 2005-12-08
DE602005025755D1 (en) 2011-02-17
PL1750862T3 (en) 2011-06-30
JP2008501680A (en) 2008-01-24
CA2568640A1 (en) 2005-12-15
JP2011252022A (en) 2011-12-15
IL179718A0 (en) 2007-05-15
ATE493973T1 (en) 2011-01-15
EP1750862A4 (en) 2008-06-11
JP4880591B2 (en) 2012-02-22
EP1750862B1 (en) 2011-01-05
AU2005249794A1 (en) 2005-12-15
US20120238555A1 (en) 2012-09-20
EP1750862A2 (en) 2007-02-14
CA2568640C (en) 2011-08-09
WO2005118166A2 (en) 2005-12-15
US8226977B2 (en) 2012-07-24
US8414920B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
WO2005118166A3 (en) Pharmaceutical composition containing irbesartan
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MY143795A (en) Tetrahydropyridoindole derivatives
WO2004033418A3 (en) Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
WO2007048219A3 (en) Sustained drug release composition
EA018193B3 (en) Compounds and pharmaceutical compositions for reducing uric acid level
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2004108162A3 (en) Controlled release pharmaceutical composition
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2006060711A3 (en) Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
WO2006118948A3 (en) Therapeutic compositions
TW200517106A (en) Sustained release pharmaceutical compositions
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2010038091A3 (en) Compositions comrrising amlodipine and bisoprolol
WO2005058890A3 (en) Hydronopol derivatives as agonists on human orl1 receptors
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
WO2006021401A3 (en) Bicylononene derivatives
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations
WO2003045305A3 (en) Acetaminophen compositions
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
WO2004032843A3 (en) Mucoadhesive tetracycline formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005775601

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 7846/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005249794

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 179718

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2568640

Country of ref document: CA

Ref document number: 2007514218

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005249794

Country of ref document: AU

Date of ref document: 20050602

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005249794

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005775601

Country of ref document: EP